Occult hepatitis B virus infection among Egyptian blood donors

作     者：Zeinab N Said Manal H El Sayed Iman I Salama Enas K Aboel-Magd Magda H Mahmoud Maged El Setouhy Faten Mouftah Manal B Azzab Heidi Goubran Amal Bassili Gamal E Esmat 

作者机构：Microbiology and Immunology DepartmentFaculty of Medicine(for Girls)AlAzhar University11511 CairoEgypt Pediatric DepartmentHematology/Oncology DivisionFaculty of MedicineAin Shams University11511 CairoEgypt Community Medicine DepartmentNational Research Center12411 GizaEgypt Ain-Shams Maternity and Women's University Hospital11511 CairoEgypt CommunityEnviromental and Occupational Medicine DepartmentFaculty of MedicineAin Shams University11511 CairoEgypt National Blood Transfusion Center11511 CairoEgypt TB Surveillance officerSTB/WHO/EMRO.Focal pointTropical Disease Research11511 CairoEgypt Tropical Medicine DepartmentFaculty of Medicine-Cairo University11511 CairoEgypt 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2013年第5卷第2期

页      面：64-73页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：WHO Eastern Mediterranean Region WHO special program for Research and Training in Tropical Diseases: The EMRO/TDR Small Grants Scheme for Operational research in Tropical and other communicable Disease QIAGEN Division of Communicable Disease 

主　　题：Hepatitis B virus Total anti-HBc Occult hepatitis B virus infection Hepatitis B surface antigen Hepatitis B virus-DNA 

摘      要：AIM:To identify blood donors with occult hepatitis B virus(HBV) infection(OBI) to promote safe blood ***:Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen(HBsAg),hepatitis C antibody(HCV Ab) and human immunodeficiency virus *** were subjected to the detection of alanine aminotransferase(ALT) and aspartate transaminase(AST) and screening for anti-HBV core antibodies(total) by two different techniques;[Monoliza antibodies to hepatitis B core(Anti-HBc) Plus-Bio-Rad] and(ARC-HBc total-ABBOT).Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface(anti-HBs)(ETI-AB-AUK-3,Dia Sorin-Italy).Serum anti-HBs titers 10 IU/L was considered *** HBV DNA by real time polymerase chain reaction(PCR)(QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were 1000 IU/***,265 recipients were included,34 of whom were followed up for 3-6 *** were investigated for ALT and AST,HBV serological markers:HBsAg(ETI-MAK-4,Dia Sorin-Italy),anti-HBc,quantitative detection of anti-HBs and ***:525/3167(16.6%) of blood units were positive for total anti-HBc,64% of those were antiHBs *** by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples,where 451(90.6%) confirmed *** for anti-HBc was considered confirmed only if two positive results were obtained for each sample,giving an overall prevalence of 451/3167(14.2%) for total *** DNA was quantified by real time PCR in 52/303(17.2%) of anti-HBc positive blood donors(viral load range:5 to 3.5 x 105 IU/mL) with a median of 200 IU/mL(mean:1.8 x 104 ± 5.1 x 104 IU/mL).AntiHBc was the only marker in 68.6% of *** and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity a